Dual-Energy CTA with High-Concentration Contrast Material

JRCT ID: jRCTs041230098

Registered date:27/10/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Aortic diseases
• Date of first enrollment: 16/11/2023
• Target sample size: 100
• Study type: Interventional

Intervention(s)

Arm A: Iopromide 300 mgI/mL intravenously given and perform dual-energy CTA
Arm B: Iopromide 370 mgI/mL intravenously given and perform dual-energy CTA

Outcome(s)

• Primary Outcome: Arterial visualization score for iliolumber artery on 3D VR images
• Secondary Outcome: Arterial visualization scores except for iliolumber artery (brachiocephalic, common carotid, subclavian, bronchial, internal thoracic, intercostal, common hepatic, proper hepatic, splenic, left gastric, gastroduodenal, inferior phrenic, superior mesenteric, inferior mesenteric, renal, lumbar, external iliac, internal iliac, superior gluteal, inferior gluteal, obturator, and inferior epigastric arteries) on 3d VR images and for all arteried described above on axial and coronal images, CT attenuations of arteries, image noise, signal-to-noise ratio, and image quality.

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1. Over 18 years old (any men and women)
2. Planned for aortic CTA (screening or follow-up for aortic aneurysm, aortic dissection, etc.)
3. Written informed consent

Exclude criteria

1. Over 90 kg
2. Past history of hypersensitivity reaction to contrast material
3. pregnant woman
4. eGFR < 30 mL/min/1.73m2

Related Information

• Primary Sponsor: Noda Yoshifumi
• Source(s) of Monetary Support: Bayer Yakuhin, Ltd.